CLINUVEL PHARMACEUTICALS LTD (Seite 890)
eröffnet am 24.04.07 13:00:35 von
neuester Beitrag 04.05.24 10:03:08 von
neuester Beitrag 04.05.24 10:03:08 von
Beiträge: 22.262
ID: 1.126.403
ID: 1.126.403
Aufrufe heute: 102
Gesamt: 4.024.995
Gesamt: 4.024.995
Aktive User: 0
ISIN: AU000000CUV3 · WKN: A0JEGY · Symbol: UR9
9,3650
EUR
+2,63 %
+0,2400 EUR
Letzter Kurs 15:08:38 Tradegate
Neuigkeiten
28.03.24 · globenewswire  |
07.03.24 · EQS Group AG |
05.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,1840 | +118,74 | |
| 3,2000 | +93,94 | |
| 16,550 | +37,23 | |
| 1,3300 | +30,51 | |
| 1,9800 | +27,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9500 | -13,60 | |
| 7,9100 | -16,03 | |
| 2,4820 | -21,46 | |
| 0,6900 | -21,59 | |
| 4,3300 | -68,19 |
Beitrag zu dieser Diskussion schreiben
Feedback
PW ist untragbar. Anstatt der Fa ein ordentliches Designated Sponsoring zu verpassen nur bla bla bla.
PW nimmt Clinuvel durch mit 1000 Stößen pro Minute!
!
Dieser Beitrag wurde von MadMod moderiert. Grund: auffällige/abwertende Vulgärsprache
Kurz davor, wenn der CEO nicht bald entlassen wird.
Ist die Firma Pleite gegangen?
Trading Spotlight
🤮🤮🤮🤮🤮
The Patient Perspective: A Matter of Minutes
Swiss Society for Porphyria - www.porphyria.ch
1. DEZ. 2019 —
The Patient, the scientific journal dedicated to patient-centered outcomes research, has published a commentary authored by Rocco Falchetto, describing how patient input can contribute to medical product research and development processes, regulatory reviews, health technology assessments and reimbursement decision making. The article builds directly from Falchetto’s presentation in the symposium, “Patient preferences in the medical treatment lifecycle” at the 10th Meeting of the International Academy of Health Preference Research (IAHPR) in Basel, Switzerland, on the 13th of July 2019. It focuses on the arduous years-long patient journey to access afamelanotide, illustrates challenges and opportunities in the inclusion of the patient voice in the lifecylce of medicines, and calls for a stronger integration of the patient perspective in health systems’ decision-making processes.
We look forward to the article contributing to raising awareness on the urgent need for a full integration of the perspective of patients in decisions affecting their health and well-being as well as to a better understanding of EPP and the benefits of afamelanotide. As Falchetto concludes in his article, we hope that skeptical decision makers will reconsider their views on the value of this life-changing treatment, giving those who suffer from EPP a second chance to finally step out from the shadows and into life as fully productive and engaged members of society.
https://www.change.org/p/ein-leben-ohne-sonne-vivre-sans-sol…
Swiss Society for Porphyria - www.porphyria.ch
1. DEZ. 2019 —
The Patient, the scientific journal dedicated to patient-centered outcomes research, has published a commentary authored by Rocco Falchetto, describing how patient input can contribute to medical product research and development processes, regulatory reviews, health technology assessments and reimbursement decision making. The article builds directly from Falchetto’s presentation in the symposium, “Patient preferences in the medical treatment lifecycle” at the 10th Meeting of the International Academy of Health Preference Research (IAHPR) in Basel, Switzerland, on the 13th of July 2019. It focuses on the arduous years-long patient journey to access afamelanotide, illustrates challenges and opportunities in the inclusion of the patient voice in the lifecylce of medicines, and calls for a stronger integration of the patient perspective in health systems’ decision-making processes.
We look forward to the article contributing to raising awareness on the urgent need for a full integration of the perspective of patients in decisions affecting their health and well-being as well as to a better understanding of EPP and the benefits of afamelanotide. As Falchetto concludes in his article, we hope that skeptical decision makers will reconsider their views on the value of this life-changing treatment, giving those who suffer from EPP a second chance to finally step out from the shadows and into life as fully productive and engaged members of society.
https://www.change.org/p/ein-leben-ohne-sonne-vivre-sans-sol…
"Philippe Wolgen is paid around the same as most CEOs of similar size companies."
Quelle: https://finance.yahoo.com/news/clinuvel-pharmaceuticals-limi…
Quelle: https://finance.yahoo.com/news/clinuvel-pharmaceuticals-limi…
Durchsuchen
07.03.24 · EQS Group AG · Clinuvel Pharmaceuticals |
06.01.24 · wallstreetONLINE NewsUpdate · Evotec |
06.01.24 · wallstreetONLINE Redaktion · Evotec |
04.10.23 · wO Chartvergleich · Bayer |
20.09.23 · wO Chartvergleich · Borussia Dortmund |